Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
LGND — Ligand Pharmaceuticals Incorporated
NASDAQ
FULL STOCK PAGE →

Q1 2026 Earnings Call Summary

MAY 9, 2026
REVENUE
$51.7M -13.3%
NET MARGIN
-25.8% -100.9 PTS
EPS
-$0.67 -129.5%
FREE CASH FLOW
$48.5M +5.7%

No summary has been written for this call yet.